Elaidyl-sulfamide, an oleoylethanolamide-modelled PPARα agonist, reduces body weight gain and plasma cholesterol in rats

• Hauptverfasser: Juan Manuel Decara (VerfasserIn), Miguel Romero-Cuevas (VerfasserIn), Patricia Rivera (VerfasserIn), Manuel Macias-González (VerfasserIn), Margarita Vida (VerfasserIn), Francisco J. Pavón (VerfasserIn), Antonia Serrano (VerfasserIn), Carolina Cano (VerfasserIn), Nieves Fresno (VerfasserIn), Ruth Pérez-Fernández (VerfasserIn), Fernando Rodríguez de Fonseca (VerfasserIn), Juan Suárez (VerfasserIn)
• Format: Buch
• Veröffentlicht: The Company of Biologists, 2012-09-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

SUMMARY We have modelled elaidyl-sulfamide (ES), a sulfamoyl analogue of oleoylethanolamide (OEA). ES is a lipid mediator of satiety that works through the peroxisome proliferator-activated receptor alpha (PPARα). We have characterised the pharmacological profile of ES (0.3-3 mg/kg body weight) by m...